(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 19.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Zymeworks's revenue in 2026 is $134,481,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $17,998,934,792, with the lowest ZYME revenue forecast at $7,046,233,859, and the highest ZYME revenue forecast at $28,961,738,658. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $14,159,072,233, with the lowest ZYME revenue forecast at $5,060,446,429, and the highest ZYME revenue forecast at $23,573,508,210.
In 2028, ZYME is forecast to generate $20,416,154,841 in revenue, with the lowest revenue forecast at $15,386,391,390 and the highest revenue forecast at $24,280,713,456.